{"schema_version":"secwatch.filing_event.v1","accession":"0000882095-25-000003","form_type":"8-K","ticker":"GILD","cik":"0000882095","company_name":"GILEAD SCIENCES, INC.","filed_at":"2025-02-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.646010+00:00","generated_at":"2026-05-26T23:41:19.124690+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Gilead Q4 revenue up 6% to $7.6B; full year EPS hit by $4.2B impairment","bullets":["Q4 product sales ex-Veklury +13% to $7.2B; HIV sales +16% to $5.5B, Biktarvy +21% to $3.8B.","Full year 2024 diluted EPS $0.38 vs $4.50, reflecting $4.2B Immunomedics IPR&D impairment and $3.9B CymaBay charge.","Non-GAAP diluted EPS Q4 $1.90 (+10%); full year $4.62 vs $6.72; cash, equivalents & securities $10.0B.","FY2025 guidance: product sales $28.2-28.6B; non-GAAP EPS $7.70-8.10; Veklury sales expected $1.4B.","Issued $3.5B senior notes in Q4; paid $973M dividends and repurchased $350M stock."],"urls":{"canonical":"https://secwatch.observer/filing/0000882095-25-000003","json":"https://secwatch.observer/filing/0000882095-25-000003.json","markdown":"https://secwatch.observer/filing/0000882095-25-000003.md","text":"https://secwatch.observer/filing/0000882095-25-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000003/0000882095-25-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000003/gild-20250211.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T23:41:19.124690+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}